• JULY 26, 2000

Abbott Laboratories: A healthy dose

Abbott Laboratories (India), the 51.5% Indian subsidiary of Abbott USA has reported impressive results for the first quarter ended June 2001. Pre–tax profits have jumped almost 70% on the back of a 18.5% jump in the topline.

The company has however not provided for the part of the deferred revenue expenditure, which was incurred when it paid of the workers of its Kurla plant who took a VRS when it shut down the plant. The balance meant to be written off amounts to Rs 22.28 m.

(Rs m) 1QFY00 1QFY01 Change
Sales 278 330 18.5%
Other Income 1 1 3.9%
Expenditure 260 309 18.8%
Operating Profit (EBDIT) 19 21 13.2%
Operating Profit Margin (%) 6.7% 6.4%  
Interest 7 1  
Depreciation 2 2 18.0%
Profit before Tax 11 18 69.4%
Other Adjustments      
Tax   2  
Profit after Tax/(Loss) 11 16 51.0%
Net profit margin (%) 3.9% 5.0%  
No. of Shares (m) (eoy) 2.6 2.6  
Diluted no. of shares (m) 2.6 2.6  
Diluted Earnings per share* 16.7 25.1  

Abbott India, is active in the areas of anti–infectives, dermatological (skin infection), anti–diarrhoeal and gastro–intestinal apart from a portfolio of hospital products and nutritional products. The company has introduced Hytrin in India. The product has captured over 55% market share and has been growing at over 50% over the last two years. The company’s Claribid (used in cases of upper respiratory tract infection) also has been growing at over 40% and enjoys a 35% market share.

The company has also been restructuring its operations over the last three years. And the benefits of the restructuring are being reflected in the growth in pre–tax figures.

If one were to exclude the write off of deferred revenue expenditure, the current stock price of Rs 401 implies an earning multiple of around 16 times.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407